Scientists Develop First Drug to Target Cancer's 'Immortality' RNA
Scientists at Hebrew University have developed a novel small molecule using RIBOTAC technology that selectively targets and destroys the cancer-associated RNA TERRA, slowing tumor growth and opening new avenues for RNA-based cancer therapies beyond traditional protein-focused drugs.